Overview
This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab). The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE.
Possible benefits to others include a better understanding of EoE and helping to inform research and clinical trial design leading to treatment decisions in this patient population going forward.
Patient questionnaires will measure the following:
- How EoE makes one feel
- EoE symptoms
- How EoE affects quality-of-life
- How EoE impacts aspects of daily life
- How difficult it is to swallow
- How EoE symptoms have changed throughout the study
Eligibility
Key Inclusion Criteria:
- Initiating treatment with DUPIXENT® for EoE according to the USPI
- Able to understand and complete registry-related questionnaires (including adolescents)
Key Exclusion Criteria:
- Patients who have a contraindication to DUPIXENT® according to the USPI
- Treatment with DUPIXENT® within the 6 months prior to the screening assessment
- Participation in an ongoing interventional study on or within 6 months of the baseline assessment. Once enrolled in registry, participation is allowed in other ongoing studies (at the discretion of the registry investigator)
NOTE: Other protocol defined inclusion/exclusion criteria apply